Regeneron
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
Stock Snapshot
Regeneron(REGN) stock is priced at $707.06, giving the company a market capitalization of 74.66B. It carries a P/E multiple of 16.72 and pays a dividend yield of 52.2%.
During the trading session on 2026-04-30, Regeneron(REGN) shares reached a daily high of $708.44 and a low of $680.00. At a current price of $707.06, the stock is +4.0% higher than the low and still -0.2% under the high.
Trading activity shows a volume of 1.08M, compared to an average daily volume of 845.83K.
The stock's 52-week range extends from a low of $476.49 to a high of $821.11.
The stock's 52-week range extends from a low of $476.49 to a high of $821.11.
REGN News
Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Regeneron (REGN) to $788 from $796 and keeps an Equal Weight rating on the shares. Pipel...
BMO Capital analyst Evan Seigerman maintained a Buy rating on Regeneron yesterday and set a price target of $900.00. Unlock hedge fund-level data and powerful...
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Wednesday reported first-quarter adjusted earnings of $9.47 per share, up 15% year-over-year, beating the consen...
Analyst ratings
77%
of 31 ratingsMore REGN News
AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX AD...
Technology Regeneron Slumps On An Unexpected Setback For Its Bread-And-Butter Drug Licensing Regeneron stock dipped early Wednesday after the biotech giant repo...
Regeneron (REGN) came out with quarterly earnings of $9.47 per share, beating the Zacks Consensus Estimate of $8.52 per share. This compares to earnings of $8.2...
In April 2026, Regeneron Pharmaceuticals and partner Sanofi reported a series of milestones including FDA accelerated approval for Otarmeni, expanded U.S. pedia...
The deal, announced Thursday, follows discussions at the White House involving Regeneron co-founders Leonard Schleifer and George Yancopoulos, and addresses pri...
If you are wondering whether Regeneron Pharmaceuticals at around US$766 per share still offers value, the answer depends on how you look at what the market is p...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.